A suspension gel for treating inflammatory skin diseases

By using the suspension gel form in Masacalciferol ointment, combining antioxidants and specific ingredients, the problems of greasy and thermal instability are solved, and the physical and chemical stability of Masacalciferol is improved, and the Skin absorption effect.

CN114588102BActive Publication Date: 2024-11-05NANJING HERON PHARMA SCI & TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210270877.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-03-18
Publication Date
2024-11-05
Estimated Expiration
2042-03-18

AI Technical Summary

Technical Problem

The existing masalcalciferol ointment preparations have greasy problems, poor drug compliance and thermal instability, which affect their chemical stability.

Method used

In the form of a suspension gel agent, including oil phase, aqueous phase and gel phase components, masalcithinol is used as the active ingredient, combined with butyl hydroxyanisole, propyl gallate, dl-α-tocopherol, etc. Antioxidants, medium-chain triglycerides and isopropyl myristate, etc. form O/W gels, optimize the component ratio and preparation method to improve stability and absorption effect.

Benefits of technology

It realizes the physical and chemical stability of masalcalciferol, improves skin feeling and washability, enhances the skin's absorption of drugs, and does not contaminate clothing, and has good physical and chemical stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114588102B_ABST
    Figure CN114588102B_ABST
Patent Text Reader

Abstract

The present invention provides a suspension gel for treating inflammatory skin diseases, the suspension gel comprising an oil phase component, an aqueous phase component and a gel phase component, the oil phase component comprising an active ingredient and an antioxidant; wherein the active ingredient is maxacalcitol, and the antioxidant comprises any one of butylated hydroxyanisole, propyl gallate, dl-α-tocopherol or butylated hydroxytoluene or a combination of at least two thereof. The suspension gel provided by the present invention has suitable viscosity and elasticity, is non-irritating and non-greasy to the skin, and is easily spread and washed off, does not contaminate clothing, and can be directly applied to the skin; the suspension gel provided by the present invention has excellent physical stability and chemical stability; the suspension gel provided by the present invention can improve the absorption of maxacalcitol by the skin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical chemistry, and particularly relates to a suspension gel for treating inflammatory skin diseases. Background Art

[0002] Chronic inflammatory skin diseases, particularly psoriasis, are prevalent, affecting approximately 2% of the world's population, with approximately one-third of patients developing the disease before the age of 18. Psoriasis is generally considered an autoimmune system disorder that, while not directly life-threatening, can have a direct impact on physical and mental health.

[0003] Maxacalcitol is a vitamin D3 derivative. Maxacalcitol ointment was developed and launched by Japan's Maruho Company in 2006. It is mainly used to treat psoriasis, ichthyosis, palmoplantar keratoderma, palmoplantar pustulosis, etc. The prescription composition includes anhydrous ethanol, medium-chain triglycerides and white vaseline.

[0004] However, ointment formulations present several challenges: the waxy base in the formulation is highly oily, leaving a greasy film on the skin that is difficult to clean, leading to poor patient compliance. Furthermore, the waxy carrier must be maintained at a high temperature (nearly 70°C) during the preparation process, and maxacalcitol is thermally unstable, which poses a risk to its chemical stability. To address this, creams or gels, which offer improved compliance compared to ointments, could be considered. Summary of the Invention

[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide a suspension gel for treating inflammatory skin diseases. The suspension gel provided by the present invention has excellent physical and chemical stability.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a suspension gel, comprising an oil phase component, an aqueous phase component, and a gel phase component, wherein the oil phase component comprises an active ingredient and an antioxidant;

[0008] The active ingredient is maxacalcitol, and the antioxidant includes any one of butylated hydroxyanisole, propyl gallate, dl-α-tocopherol or butylated hydroxytoluene, or a combination of at least two thereof.

[0009] In the present invention, antioxidants can improve the physical and chemical stability of the pharmaceutical composition.

[0010] The suspension gel provided by the present invention is a translucent or opaque semisolid with suitable viscosity and elasticity for easy spreading and washing off. Compared with existing ointments, it has better skin compatibility, is non-irritating and non-greasy, and is easy to spread and wash off without staining clothing. The gel can be applied directly to the skin.

[0011] Maxacalcitol, the active pharmaceutical ingredient in the suspension gel of the present invention, exists in a dissolved state in the oil phase and ultimately in the suspension gel. The dissolved state, as defined herein, means that the active pharmaceutical ingredient exists in molecular form in the oil solution and maintains good stability during preparation, transportation, storage, and use without aggregation or precipitation.

[0012] In the present invention, the suspension gel is an O / W type gel, the gel phase is equivalent to a network structure, and the O / W droplets are dispersed in the network structure.

[0013] Preferably, the mass ratio of the oil phase component, the water phase component and the gel phase component is (50-70):(6-12):(20-40), for example, it can be 50:8:20, 55:12:25, 60:10:40, 63:7:30, 52:11:22, 70:8:20, 70:12:20, 70:12:40, etc.

[0014] Preferably, the mass ratio of the active ingredient to the antioxidant is (0.001-0.2):(0.005-0.5), for example, it can be 0.001:0.005, 0.001:0.05, 0.2:0.005, 0.2:0.5, 0.1:0.1, etc.

[0015] Preferably, the oil phase component further includes low-polarity ester oil, non-polar ester oil and a co-emulsifier.

[0016] Preferably, the mass ratio of the low-polarity ester oil, the non-polar ester oil and the co-emulsifier is (10-80):(5-20):(0.5-5), for example, it can be 10:1:0.5, 10:15:0.5, 30:10:2, 50:1:0.5, 60:15:0.5, 50:15:3, etc.

[0017] Preferably, the low-polarity ester oil includes any one or a combination of at least two of isopropyl myristate, octyldodecyl myristate, decyl oleate, medium-chain triglycerides, and cetyl laurate, preferably a combination of medium-chain triglycerides and isopropyl myristate.

[0018] In the present invention, medium chain triglycerides refer to a mixture of saturated triglycerides, mainly caprylic acid (C8H 16 O2) and decanoic acid (C 10 H20 O2). Medium chain triglycerides and isopropyl myristate work together to maintain the physical and chemical stability of the suspension gel and promote the absorption of the drug by the skin.

[0019] Preferably, the mass ratio of the medium chain triglycerides and isopropyl myristate is (1-5):1, for example, it can be 1:1, 2:1, 3:1, 4:1, 5:1, etc.; preferably, it is (2-4):1, for example, it can be 2:1, 2.2:1, 2.4:1, 2.6:1, 2.8:1, 3:1, 3.2:1, 3.4:1, 3.6:1, 3.8:1, 4:1, etc.

[0020] Preferably, the non-polar ester oil includes any one of light liquid paraffin, soybean oil or olive oil, or a combination of at least two thereof, preferably light liquid paraffin.

[0021] Preferably, the antioxidant comprises any one of butylated hydroxytoluene, butylated hydroxyanisole, and dl-α-tocopherol, or a combination of at least two thereof, preferably a combination of butylated hydroxytoluene and dl-α-tocopherol or a combination of butylated hydroxyanisole and dl-α-tocopherol.

[0022] Preferably, the mass ratio of butylated hydroxytoluene and dl-α-tocopherol is (1-100):1, for example, it can be 1:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, etc.; preferably, it is (1-50):1, for example, it can be 1:1, 10:1, 20:1, 30:1, 40:1, 50:1, etc.

[0023] Preferably, the mass ratio of butylated hydroxyanisole to dl-α-tocopherol is (1-100):1, for example, 1:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, etc.; preferably, it is (1-50):1, for example, 1:1, 10:1, 20:1, 30:1, 40:1, 50:1, etc.

[0024] Preferably, the co-emulsifier includes any one or a combination of at least two of polyoxyethylene alkyl ether surfactants, polyoxyethylene castor oil surfactants, fatty acid sorbitan surfactants, polysorbate surfactants or polyglycerol fatty acid surfactants.

[0025] Preferably, the co-emulsifier includes any one of polyoxyethylene-35 castor oil, polyoxyethylene-40 stearate, Span 80, Span 20, sorbitan monolaurate or sorbitan monooleate, or a combination of at least two thereof, preferably a combination of Span 80 and polyoxyethylene-35 castor oil.

[0026] Preferably, the mass ratio of Span 80 and polyoxyethylene-35 castor oil is (0.2-5):1, for example, it can be 0.2:1, 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, etc.; further preferably, it is (0.5-1.5):1, for example, it can be 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, etc.

[0027] In the present invention, Span 80 and polyoxyethylene-35 castor oil are used as co-emulsifiers. The two cooperate with each other and synergistically enhance the effect, which can further increase the affinity between the oil phase and the water phase, jointly maintain the physical and chemical stability of the suspension gel, and promote the skin's absorption of the drug.

[0028] Preferably, the oil phase component further includes a polar solvent, and the polar solvent includes any one of ethanol, isopropanol, propylene glycol, butylene glycol, polyethylene glycol, glycerol, ethylene glycol, ethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monobutyl ether, diethylene glycol monomethyl ether or diethylene glycol monoethyl ether, or a combination of at least two thereof.

[0029] Preferably, the mass percentage of the polar solvent in the oil phase component is 1-15%, for example, it can be 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, etc.

[0030] In the present invention, the aqueous phase component includes an emulsifier and water.

[0031] Preferably, the mass ratio of the emulsifier to water is (0.5-3)(5-10), for example, it can be 0.5:5, 0.7:5, 0.7:8, 0.7:10, 1:5, 1:9, 2:5, 2:10, etc.

[0032] Preferably, the emulsifier includes any one or a combination of at least two of polyethylene glycol ester surfactants, polyoxyethylene-polyoxypropylene copolymer surfactants, polysorbate surfactants, fatty acid sorbitan surfactants, polyoxyethylene fatty acid ester surfactants or polyoxyethylene fatty alcohol ether surfactants.

[0033] Preferably, the emulsifier includes any one or a combination of at least two of 15-hydroxystearate polyethylene glycol, poloxamer 188, poloxamer 407, Tween 20, Tween 80, sorbitan monolaurate, sorbitan monooleate, polyoxyethylene-35 castor oil or polyoxyethylene-40 stearate, preferably any one or a combination of at least two of poloxamer 188, poloxamer 407 or 15-hydroxystearate polyethylene glycol, and further preferably poloxamer 188.

[0034] Preferably, the water comprises purified water and / or degassed water.

[0035] In the present invention, the gel phase components include a gelling agent, a pH regulator and water.

[0036] Preferably, the mass ratio of the gelling agent, pH regulator and water is (0.04-0.75):(0.3-3):(15-40), for example, it can be 0.04:0.3:15, 0.04:3:15, 0.04:0.3:40, 0.04:3:40, 0.75:0.3:15, 0.75:3:15, 0.75:0.3:40, 0.75:3:40, etc.

[0037] Preferably, the gelling agent comprises any one or a combination of at least two of carbomer, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, SEPINEO P600, starch gelatinized gel matrix, xanthan gum, sodium alginate, tragacanth gum, guar gum or locust bean gum, preferably carbomer.

[0038] In the present invention, SEPINEO P 600 is a novel polymer mixture for topical preparations, comprising acrylamide, sodium propylene dimethyl taurate copolymer, and polysorbate 80. Its mass content in suspension gels may be 1-10%, for example, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, etc.; preferably 3-8%, for example, 3%, 4%, 5%, 6%, 7%, 8%, etc.

[0039] Preferably, the carbomer includes carbomer Tr-1 and / or carbomer Tr-2, preferably carbomer Tr-1.

[0040] Preferably, the pH adjuster includes any one or a combination of at least two of sodium hydroxide, acetic acid, citric acid, triethanolamine, diethanolamine, disodium hydrogen phosphate or sodium dihydrogen phosphate, preferably any one or a combination of at least two of triethanolamine, citric acid and sodium hydroxide.

[0041] Preferably, the water comprises purified water and / or degassed water.

[0042] Preferably, the pH value of the gel phase is 5.0-7.5, for example, it can be 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, etc.; preferably, it can be 5.5-7.0, for example, it can be 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, etc.

[0043] The present invention takes into account that the pH of the skin surface is acidic (4.2-5.6) and gradually becomes neutral (about 7.4) in the deeper layers of the skin. The pH value of psoriasis lesions is 5.69±0.61. Therefore, the pH range of the topical preparation for treating psoriasis can be 5.0-7.5. Taking into account the physicochemical stability and rheological profile of the final preparation, the pH value is preferably 5.5-7.0. Therefore, the present invention adjusts the pH of the gel phase to 5.5-7.0 by adding a pH adjuster to the gel matrix.

[0044] Preferably, the average particle size of the suspension gel is 0.1-20 μm, for example, it can be 0.1 μm, 1 μm, 3 μm, 5 μm, 7 μm, 9 μm, 11 μm, 13 μm, 15 μm, 17 μm, 20 μm, etc.; more preferably, it is 1-10 μm, for example, it can be 1 μm, 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm, 10 μm, etc.

[0045] As a preferred technical solution of the present invention, the suspension gel comprises the following components by weight percentage:

[0046]

[0047]

[0048] In the present invention, the mass percentage of maxacalcitol is 0.0001-0.01%, for example, it can be 0.0001%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, etc.

[0049] In the present invention, the mass percentage of the low-polarity ester oil is 10-80%, for example, it can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, etc.

[0050] In the present invention, the mass percentage of the non-polar ester oil is 5-20%, for example, it can be 5%, 7%, 9%, 11%, 13%, 15%, 17%, 19%, 20%, etc.

[0051] In the present invention, the mass percentage of the polar solvent is 1-15%, for example, it can be 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, etc.

[0052] In the present invention, the mass percentage of the antioxidant is 0.005-0.5%, for example, it can be 0.005%, 0.01%, 0.05%, 0.07%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, etc.

[0053] In the present invention, the mass percentage of the co-emulsifier is 0.5-3%, for example, it can be 0.5%, 0.7%, 1%, 1.5%, 2%, 2.5%, 3%, etc.

[0054] In the present invention, the mass percentage of the emulsifier is 0.5-3%, for example, it can be 0.5%, 0.7%, 1%, 1.5%, 2%, 2.5%, 3%, etc.

[0055] In the present invention, the mass percentage of the gelling agent is 0.04-0.75%, for example, it can be 0.04%, 0.08%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.75%, etc.

[0056] In the present invention, the mass percentage of the pH adjuster is 0.3-3%, for example, it can be 0.3%, 0.8%, 1%, 1.5%, 2%, 2.5%, 3%, etc.

[0057] In the present invention, the mass percentage of water is 10-60%, for example, it can be 10%, 20%, 30%, 40%, 50%, 60%, etc.

[0058] As a further preferred technical solution of the present invention, the suspension gel comprises the following components by mass percentage:

[0059]

[0060] In the present invention, the mass percentage of maxacalcitol is 0.0001-0.01%, for example, it can be 0.0001%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, etc.

[0061] In the present invention, the mass percentage of medium chain triglycerides is 20-30%, for example, it can be 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, etc.

[0062] In the present invention, the mass percentage of isopropyl myristate is 5-15%, for example, it can be 5%, 7%, 9%, 11%, 13%, 15%, etc.

[0063] In the present invention, the mass percentage of light liquid paraffin is 10-20%, for example, it can be 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.

[0064] In the present invention, the mass percentage of the antioxidant is 0.005-0.5%, for example, it can be 0.005%, 0.01%, 0.05%, 0.07%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, etc.

[0065] In the present invention, the mass percentage of Span 80 is 0.5-2%, for example, it can be 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, etc.

[0066] In the present invention, the mass percentage of polyoxyethylene-35 castor oil is 0.5-2%, for example, it can be 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, etc.

[0067] In the present invention, the mass percentage of Poloxamer 188 is 0.5-3%, for example, it can be 0.5%, 0.7%, 1.1%, 1.3%, 1.5%, 1.7%, 1.9%, 2.1%, 2.3%, 2.5%, 2.7%, 3%, etc.

[0068] In the present invention, the mass percentage of the polar solvent is 5-15%, for example, it can be 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, etc.

[0069] In the present invention, the mass percentage of carbomer Tr-1 is 0.04-0.75%, for example, it can be 0.04%, 0.08%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.75%, etc.

[0070] In the present invention, the mass percentage of the pH adjuster is 0.3-3%, for example, it can be 0.3%, 0.8%, 1%, 1.5%, 2%, 2.5%, 3%, etc.

[0071] In the present invention, the mass percentage of water is 15-45%, for example, it can be 15%, 30%, 35%, 40%, 45%, etc.

[0072] In a second aspect, the present invention provides a method for preparing the suspension gel as described in the first aspect, the method for preparing the suspension gel comprising the following steps: mixing an oil phase component, an aqueous phase component and a gel phase component to obtain the suspension gel.

[0073] Preferably, the mixing temperature is 15-40°C, for example, 15°C, 20°C, 25°C, 30°C, 35°C, 40°C, etc.; the mixing time is 0.3-20h, for example, 0.3h, 1h, 3h, 5h, 7h, 9h, 11h, 13h, 15h, 17h, 20h, etc.

[0074] In the present invention, the method for preparing the oil phase component comprises the following steps: mixing maxacalcitol, low-polarity ester oil, non-polarity ester oil, polar solvent, antioxidant and co-emulsifier to obtain the oil phase component.

[0075] Preferably, the mixing temperature for obtaining the oil phase components is 25-35°C, for example, it can be 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, etc.; the mixing time is 1.5-2.5h, for example, it can be 1.5h, 1.6h, 1.7h, 1.8h, 1.9h, 2h, 2.1h, 2.2h, 2.3h, 2.4h, 2.5h, etc.

[0076] Preferably, the method for preparing the aqueous phase component comprises the following steps: mixing an emulsifier and water to obtain the aqueous phase component.

[0077] Preferably, the mixing temperature of the aqueous phase component is 25-35°C, for example, it can be 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, etc.; the mixing time is 0.1-1h, for example, it can be 0.1h, 0.2h, 0.3h, 0.4h, 0.5h, 0.6h, 0.7h, 0.8h, 0.9h, 1h, etc.

[0078] Preferably, the preparation method of the gel phase component comprises the following steps: dispersing the gelling agent into water, adding a pH regulator and mixing after the gelling agent is completely swollen, to obtain the gel phase component.

[0079] Preferably, the mixing temperature of the gel phase components is 25-35°C, for example, it can be 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, etc.; the mixing time is 5-10h, for example, it can be 5h, 6h, 7h, 8h, 9h, 10h, etc.

[0080] In the present invention, the preparation method of the suspension gel comprises the following steps: mixing and emulsifying the oil phase component and the water phase component, and then adding the gel phase component and mixing to obtain the suspension gel.

[0081] Preferably, the emulsification temperature is 15-40°C, for example, it can be 15°C, 20°C, 25°C, 30°C, 35°C, 40°C, etc.; the time is 0.5-5h, for example, it can be 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, etc.

[0082] Preferably, the temperature for mixing the added gel phase components is 25-35°C, for example, it can be 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, etc.; the time is 0.5-2h, for example, it can be 0.5h, 0.7h, 0.9h, 1.1h, 1.3h, 1.5h, 1.7h, 1.9h, 2h, etc.

[0083] In a third aspect, the present invention provides a use of the suspension gel as described in the first aspect in preparing a medicament for treating inflammatory skin.

[0084] In the present invention, the impurities in the maxacalcitol oil phase include 5E-trans-maxacalcitol isomer and precursor-maxacalcitol.

[0085] The structural formula of the compound involved in the present invention is as follows:

[0086]

[0087] In the present invention, a compatibility study of raw materials and auxiliary materials was conducted. After mixing Maxacalcitol (MS) with the corresponding auxiliary materials, the mixture was placed at 25°C and 40°C for 21 days, and the changes of the relevant substances were measured. Table 1 shows the compatibility test results of the raw materials and auxiliary materials in the oil phase containing Maxacalcitol.

[0088] Table 1 Compatibility test results of maxacalcitol oil phase raw materials and auxiliary materials

[0089]

[0090]

[0091] The above results show that: maxacalcitol has good compatibility with medium-chain triglycerides, isopropyl myristate, light liquid paraffin, and diethylene glycol monoethyl ether, and it is necessary to add any one or a combination of at least two of the antioxidants butylated hydroxytoluene, butylated hydroxyanisole, or dl-α-tocopherol; and maxacalcitol has good compatibility with polyglycerol oleate, polysorbate 80, sorbitan monolaurate, sorbitan monooleate, polyoxyethylene-35 castor oil, and polysorbate 20.

[0092] Compared with the prior art, the present invention has the following beneficial effects:

[0093] (1) The active pharmaceutical ingredient, maxacalcitol, in the suspension gel provided by the present invention is dissolved in the maxacalcitol oil phase in a dissolved state and ultimately exists in the suspension gel in a dissolved state. It can maintain good stability during preparation, transportation, storage, and use without aggregation or precipitation.

[0094] (2) The suspension gel provided by the present invention has suitable viscosity and elasticity, is non-irritating and non-greasy to the skin, is easy to spread and wash off, does not stain clothing, and can be directly applied to the skin;

[0095] (3) The suspension gel provided by the present invention has excellent physical and chemical stability;

[0096] (4) The suspension gel provided by the present invention can improve the skin's absorption of maxacalcitol. BRIEF DESCRIPTION OF THE DRAWINGS

[0097] Figure 1 This is a microscope picture of the suspension gel provided in Example 1 on day 0.

[0098] Figure 2 This is a microscope picture of the suspension gel provided in Example 1 after being stored at 40°C for 180 days.

[0099] Figure 3 This is the HPLC chromatogram of the sample prepared in Example 1 after being stored at 40°C for 180 days. DETAILED DESCRIPTION

[0100] The technical solution of the present invention is further described below by way of specific embodiments. It should be understood by those skilled in the art that the embodiments are merely to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0101] The mass percentages of the components in the following examples are all percentages of the components in the total mass of the suspension gel.

[0102] Example 1

[0103] This embodiment provides a suspension gel, the total mass of the suspension gel is 500 g, and the raw and auxiliary materials for preparing the suspension gel include the following components in percentage by mass:

[0104]

[0105] The preparation method of the suspension gel comprises the following steps:

[0106] (1) Dissolving maxacalcitol in a mixed solvent of caprylic capric triglyceride, isopropyl myristate, light liquid paraffin, and diethylene glycol monoethyl ether according to the prescribed amount, then adding butylated hydroxytoluene, dl-α-tocopherol, Span 80, and polyoxyethylene-35 castor oil and mixing at 25° C. for 2 h to obtain an oil phase;

[0107] (2) Poloxamer 188 and purified water were mixed at 25°C for 0.5 h to obtain an aqueous phase;

[0108] (3) Dispersing Carbomer Tr-1 in water according to the prescribed amount, adding triethylamine alcohol to adjust the pH to 6.0 after complete swelling, and mixing for 8 hours to obtain a gel phase;

[0109] (4) The oil phase prepared in step (1) was added to the water phase prepared in step (2), and the mixture was emulsified at 30° C. for 2.0 h. Then, the gel phase prepared in step (3) was added, and the mixture was mixed at 25° C. for 1.1 h to prepare the suspension gel.

[0110] Example 2

[0111] This embodiment provides a suspension gel, the total mass of the suspension gel is 1000 g, and the raw and auxiliary materials for preparing the suspension gel include the following components in percentage by mass:

[0112]

[0113] The preparation method of the suspension gel comprises the following steps:

[0114] (1) Dissolving maxacalcitol in a mixed solvent of caprylic capric triglyceride, isopropyl myristate, light liquid paraffin, and diethylene glycol monoethyl ether according to the prescribed amount, then adding butylated hydroxytoluene, dl-α-tocopherol, Span 80, and polyoxyethylene-35 castor oil and mixing at 25° C. for 2 h to obtain an oil phase;

[0115] (2) Poloxamer 188 and purified water were mixed at 25°C for 0.5 h to obtain an aqueous phase;

[0116] (3) Dispersing Carbomer Tr-1 in water according to the prescribed amount, adding triethylamine alcohol to adjust the pH to 6.0 after complete swelling, and mixing for 8 hours to obtain a gel phase;

[0117] (4) The oil phase prepared in step (1) was added to the water phase prepared in step (2), and the mixture was emulsified at 30° C. for 2.0 h. Then, the gel phase prepared in step (3) was added, and the mixture was mixed at 25° C. for 1.1 h to prepare the suspension gel.

[0118] Example 3

[0119] This embodiment provides a suspension gel, the total mass of the suspension gel is 1000 g, and the raw and auxiliary materials for preparing the suspension gel include the following components in percentage by mass:

[0120]

[0121] The preparation method of the suspension gel comprises the following steps:

[0122] (1) Dissolving maxacalcitol in a mixed solvent of caprylic capric triglyceride, isopropyl myristate, light liquid paraffin, and diethylene glycol monoethyl ether according to the prescribed amount, then adding butylated hydroxytoluene, dl-α-tocopherol, Span 80, and polyoxyethylene-35 castor oil and mixing at 25° C. for 2 h to obtain an oil phase;

[0123] (2) Poloxamer 188 and purified water were mixed at 25°C for 0.5 h to obtain an aqueous phase;

[0124] (3) Dispersing Carbomer Tr-1 in water according to the prescribed amount, adding sodium hydroxide to adjust the pH to 6.0 after complete swelling, and mixing for 8 hours to obtain a gel phase;

[0125] (4) The oil phase prepared in step (1) was added to the water phase prepared in step (2), and the mixture was emulsified at 30° C. for 2.0 h. Then, the gel phase prepared in step (3) was added, and the mixture was mixed at 25° C. for 1.1 h to prepare the suspension gel.

[0126] Example 4

[0127] This embodiment provides a suspension gel, which differs from Example 1 only in that the low-polarity ester oil is 32.40 wt % octyldodecyl myristate, and the other components and preparation method are the same as those in Example 1.

[0128] Example 5

[0129] This embodiment provides a suspension gel, which differs from Example 1 only in that the low-polarity ester oil is 16.20 wt % of caprylic capric triglyceride and 16.20 wt % of isopropyl myristate, and the other components and preparation method are the same as those in Example 1.

[0130] Example 6

[0131] This embodiment provides a suspension gel, which differs from Example 1 only in that the low-polarity ester oil is 28.35 wt % of caprylic capric triglyceride and 4.05 wt % of isopropyl myristate. Other components and preparation methods are the same as those in Example 1.

[0132] Example 7

[0133] This embodiment provides a suspension gel, which differs from Example 1 only in that the antioxidant is 0.085 wt % butylated hydroxytoluene, and the other components and preparation methods are the same as those in Example 1.

[0134] Example 8

[0135] This embodiment provides a suspension gel, which differs from Example 1 only in that the antioxidant is 0.085 wt % dl-α-tocopherol, and the other components and preparation methods are the same as those in Example 1.

[0136] Example 9

[0137] This embodiment provides a suspension gel, which differs from Example 1 only in that the co-emulsifier is 1.4 wt % of Span 20, and the other components and preparation methods are the same as those in Example 1.

[0138] Example 10

[0139] This embodiment provides a suspension gel, which differs from Example 1 only in that the co-emulsifier is 1.4 wt % of Span 80, and the other components and preparation methods are the same as those in Example 1.

[0140] Example 11

[0141] This embodiment provides a suspension gel, which differs from Example 1 only in that the auxiliary emulsifier is 1.4 wt % polyoxyethylene-35 castor oil, and the other components and preparation methods are the same as those in Example 1.

[0142] Example 12

[0143] This embodiment provides a suspension gel, which differs from Example 1 only in that the co-emulsifier is 0.3 wt % of Span 80 and 1.1 wt % of polyoxyethylene-35 castor oil. Other components and preparation methods are the same as those in Example 1.

[0144] Example 13

[0145] This embodiment provides a suspension gel, which differs from Example 1 only in that the co-emulsifier is 1.1 wt% of Span 80 and 0.3 wt% of polyoxyethylene-35 castor oil. Other components and preparation methods are the same as those in Example 1.

[0146] Example 14

[0147] This embodiment provides a suspension gel, which differs from Example 1 only in that the polar solvent in the oil phase is 10.56 wt % propylene glycol, and the other components and preparation methods are the same as those in Example 1.

[0148] Example 15

[0149] This embodiment provides a suspension gel, which differs from Example 1 only in that the gel contains 0.3 wt % polyacrylic acid (Ultrez 10-Noveon), and the other components and preparation methods are the same as those in Example 1.

[0150] Example 16

[0151] This embodiment provides a suspension gel, which differs from embodiment 1 only in that the emulsification temperature in step (3) is 10° C., and the other preparation methods are the same as embodiment 1.

[0152] Example 17

[0153] This embodiment provides a suspension gel, which differs from embodiment 1 only in that the emulsification temperature in step (3) is 50° C., and the other preparation methods are the same as embodiment 1.

[0154] Example 18

[0155] This embodiment provides a suspension gel, which differs from Example 1 only in that the emulsifier is 0.7 wt % of Poloxamer 407, and the other preparation methods are the same as Example 1.

[0156] Example 19

[0157] This embodiment provides a suspension gel, which differs from Example 1 only in that the emulsifier is 0.7 wt % hydrogenated castor oil / polyethylene glycol, and the other preparation methods are the same as Example 1.

[0158] Comparative Example 1

[0159] This embodiment provides a suspension gel, which differs from Example 1 only in that it does not contain an antioxidant, the mass percentage of light liquid paraffin is 19.09%, and the other components and preparation method are the same as Example 1.

[0160] Test Example 1

[0161] Appearance and physical stability test

[0162] (1) Appearance, cold stability, heat stability and centrifugal stability tests

[0163] Test method: The appearance, cold stability, heat stability and centrifugal stability of the paste are used as assessment indicators, and scores are given according to the standards. The full score for the comprehensive score is 90 points, of which 30 points are for appearance (10 points for glossiness, 10 points for fineness and 10 points for spreadability), and 60 points are for stability (20 points for centrifugal stability, 20 points for heat stability and 20 points for cold stability).

[0164] (1) Appearance

[0165] After preparation, the appearance properties are tested after 24 hours, mainly including glossiness, fineness and spreadability. The scoring standard is "9-10 points" for glossy, uniform and fine without graininess, easy to spread, no whitening, and refreshing; "6-8 points" for moderate glossiness, small particles, and moderate spreadability; "below 6 points" for dullness, large particles, bubbles, difficult to spread, whitening, and obvious greasy feeling.

[0166] (2) Cold resistance and stability

[0167] The samples were divided into colorless transparent vials, sealed, and stored at -20°C for 24 h. The samples were taken out and observed for oil-water separation and for enlargement of the droplets using a microscope.

[0168] (3) Heat resistance and stability

[0169] The samples were divided into colorless transparent vials, sealed, and incubated at 40°C for 24 h. The samples were taken out and observed for oil-water separation and for enlargement of the droplets using a microscope.

[0170] (4) Centrifugal stability

[0171] Take an appropriate amount of paste into a centrifuge tube, centrifuge at 2500rpm for 30 minutes, and observe whether oil-water separation occurs. The test results are shown in Table 2:

[0172] Table 2 Appearance and physical stability test results

[0173]

[0174] (2) Color, pH, viscosity and average droplet size test

[0175] Test method:

[0176] (1) Color test:

[0177] Place the samples at room temperature of 20°C for 0 days and 180 days, observe the samples with the naked eye, and record the color of the paste.

[0178] (2) pH test:

[0179] After placing the paste in a beaker, adjust the paste temperature to 40°C in a 40°C water bath. Clean and dry the electrode tip of the pH meter, insert it into the paste and immerse the electrode to measure the pH. Test the pH at 40°C after 0 days and 180 days.

[0180] (3) Viscosity measurement:

[0181] Shear rate sweep tests were performed on the samples at 40°C using a constant shear mode, and the relationship between viscosity and shear rate was determined. Before the test began, the samples were equilibrated at the test temperature for 3 minutes. A rotational time sweep was selected, with a shear rate of 50 1 / s, a measurement time of 30 seconds, and a gap of 1 mm. Viscosities were measured at 40°C after 0 days and 180 days.

[0182] (4) Determination of droplet size:

[0183] Take an appropriate amount of sample and place it on a glass slide, place a cover slip on it, and observe it under a microscope at 10×40 magnification. Measure the droplet size within the field of view and calculate the average value. Measure the average droplet size at 40°C after 0 days and 180 days.

[0184] Δ(N 180d -N 0d ) = pH of the pharmaceutical composition after 180 days at 40° C. - pH of the pharmaceutical composition after 0 days;

[0185] Δ(P 180d -P 0d ) = viscosity of the pharmaceutical composition after 180 days at 40° C. - viscosity of the pharmaceutical composition after 0 days;

[0186] Δ(D 180d -D 0d ) = average droplet size of the pharmaceutical composition after being placed at 40°C for 180 days - average droplet size of the pharmaceutical composition after being placed for 0 days; the test results are shown in Table 3:

[0187] Table 3 Color, pH, viscosity and average droplet size test results

[0188]

[0189] It can be seen from the data in Table 2 and Table 3 that the suspension gel provided by the preferred technical solution of the present invention (Examples 1-3) can maintain the appearance, shape and physical stability of the suspension gel.

[0190] Figure 1 This is a microscope picture of the suspension gel provided in Example 1 on day 0. Figure 2This is a microscopic image of the suspension gel provided in Example 1 after being stored at 40°C for 180 days. It can be seen from the figure that there is no significant difference in the maximum droplet size at day 0 and after being stored at 40°C for 180 days.

[0191] By comparing Example 1 with Examples 4-6, it can be seen that when the low-polarity ester oil is not within the preferred range, the appearance and physical stability of the suspension gel will be affected; this indicates that the specific ratio of caprylic capric triglyceride and isopropyl myristate cooperates with each other to improve the physical stability of the suspension gel.

[0192] By comparing Example 1 with Examples 7-8, it can be seen that when the antioxidant is not within the preferred range, the physical stability of the suspension gel will be affected; in the present invention, butylated hydroxytoluene (or butylated hydroxyanisole) and dl-α-tocopherol cooperate with each other to synergistically enhance the effect and jointly maintain the physical stability of the suspension gel.

[0193] By comparing Example 1 with Examples 9-13, it can be seen that the specific ratio of Span 80 and polyoxyethylene-35 castor oil cooperate with each other to achieve synergistic effect and maintain the physical stability of the suspension gel.

[0194] By comparing Example 1 and Example 14, it can be seen that when the polar solvent in the oil phase is not within the preferred range, the physical stability of the suspension gel will be affected; using diethylene glycol monoethyl ether as a polar solvent can increase the dissolution rate of maxacalcitol and maintain the physical stability of the suspension gel.

[0195] By comparing Example 1 and Example 15, it can be seen that using Carbomer Tr-1 as a gelling agent can maintain the physical stability of the suspension gel.

[0196] By comparing Example 1 with Examples 16 to 17, it can be seen that the emulsification temperature affects the appearance and physical stability of the suspension gel.

[0197] By comparing Example 1 with Examples 18 to 19, it can be seen that the choice of emulsifier will affect the appearance and physical stability of the suspension gel.

[0198] It can be seen from the above experimental data that the various components of the present invention cooperate with each other, synergistically enhance the effect, and jointly maintain the physical stability of the suspension gel.

[0199] Test Example 2

[0200] Chemical stability test

[0201] Test method: High performance liquid chromatography (HPLC) was used to test the change in the content of maxacalcitol in the suspension gel after it was placed at 40°C for 180 days.

[0202] in:

[0203]

[0204] The drug is maxacalcitol.

[0205] The content of maxacalcitol was measured as follows (operation in the dark):

[0206] The mobile phase was water-acetonitrile (35:65), the chromatographic column was Amethyst C18-H, the column length was 150 mm, the inner diameter was 4.6 mm, the column temperature was 30 °C, the wavelength was 265 nm, the flow rate was 1.0 mL / min, the injection volume was 100 μL, and the analysis time was 12 min.

[0207] Δ(N 180d- N 0d ) = (maxacalcitol content in the suspension gel after 180 days at 40° C. - maxacalcitol content in the suspension gel after 0 days)

[0208] The test results are shown in Table 4:

[0209] Table 4 Chemical stability test results

[0210]

[0211] It can be seen from the data in Table 4 that the content of maxacalcitol in the suspension gel provided by the present invention (Examples 1-19) decreased by 0.18-5.45% after being placed at 40°C for 180 days; the content of maxacalcitol in the suspension gel provided by the preferred technical solution of the present invention (Examples 1-3) decreased by 0.18-0.36% after being placed at 40°C for 180 days.

[0212] Figure 3 This is the HPLC chromatogram of the suspension gel provided in Example 1 after being stored at 40° C. for 180 days. The peak time of maxacalcitol is 21.203 min.

[0213] By comparing Example 1 with Examples 4-6, it can be seen that when the low-polarity ester oil is not within the preferred range, the content of maxacalcitol in the suspension gel will be affected; this indicates that the specific ratio of caprylic capric triglyceride and isopropyl myristate cooperates with each other to improve the chemical stability of the suspension gel.

[0214] By comparing Example 1 with Examples 7-8, it can be seen that when the antioxidant is not within the preferred range, the chemical stability of the suspension gel will be affected; in the present invention, butylated hydroxytoluene (or butylated hydroxyanisole) and dl-α-tocopherol cooperate with each other to synergistically enhance the effect and jointly maintain the chemical stability of the suspension gel.

[0215] A comparison of Example 1 with Examples 9-13 demonstrates that the specific ratios of Span 80 and polyoxyl-35 castor oil exhibit different HLB values, resulting in improved compatibility between the oil and aqueous phases, uniform droplet distribution, and superior stability. The synergistic effect of Span 80 and polyoxyl-35 castor oil maintains the chemical stability of the suspension gel.

[0216] By comparing Example 1 and Example 14, it can be seen that when the polar solvent in the oil phase is not within the preferred range, the chemical stability of the suspension gel will be affected; using diethylene glycol monoethyl ether as a polar solvent can increase the dissolution rate of maxacalcitol and maintain the chemical stability of the suspension gel.

[0217] By comparing Example 1 and Example 15, it can be seen that using Carbomer Tr-1 as a gelling agent can maintain the chemical stability of the suspension gel.

[0218] By comparing Example 1 with Examples 16 to 17, it can be seen that the emulsification temperature affects the chemical stability of the suspension gel.

[0219] By comparing Example 1 with Examples 18 to 19, it can be seen that the selection of emulsifier will affect the chemical stability of the suspension gel.

[0220] From the above experimental data, it can be seen that the various components of the present invention cooperate with each other, synergistically enhance the effect, and jointly maintain the chemical stability of the suspension gel.

[0221] Test Example 3

[0222] In vivo percutaneous absorption test in hairless mice

[0223] Test method: Under anesthesia, a plastic frame (4cm 2 ) was fixed on a hairless mouse. After transdermal application of 20 mg of the suspension gel (1 μg of maxacalcitol) into the frame, the frame was fixed with an adhesive bandage. After 4 hours, the skin surface of the application part was wiped clean with cotton soaked in 70% ethanol under anesthesia. After the hairless mouse was bled to death, the skin surface of the application part was collected. The collected skin was homogenized in acetonitrile, and the liquid phase was collected. After the liquid phase was dried and solidified, it was dissolved in a dissolving solvent (acetonitrile) to prepare a sample solution. The sample solution was determined by liquid chromatography / tandem mass spectrometry (LC / MS) to calculate the maxacalcitol concentration in the skin; LC test conditions: the same as test example 2; MS test conditions: electrospray ionization source, positive ion mode; 5 parallel tests were set up for each group of tests and the average value was taken;

[0224] The test results of maxacalcitol concentration in skin are shown in Table 5:

[0225] Table 5 Test results of maxacalcitol concentration in skin

[0226]

[0227]

[0228] As can be seen from the data in Table 5, the maxacalcitol content in the skin after 4 hours of using the suspension gel provided by the present invention (Examples 1-19) was 18.34-94.23 ng / g; the maxacalcitol content in the skin after 4 hours of using the suspension gel provided by the preferred technical solution of the present invention (Examples 1-3) was 78.70-94.23 ng / g.

[0229] The suspension gel provided by the preferred technical solution of the present invention (Examples 1-3) can improve the skin's absorption of maxacalcitol ester in the suspension gel; the various components of the present invention cooperate with each other, synergistically enhance the effect, and jointly improve the skin's absorption of maxacalcitol in the suspension gel.

[0230] Test Example 4

[0231] Skin irritation test

[0232] Test method: Shave the rabbit's abdominal hair and select intact skin for a 4-week local toxicity and irritation test. Observe and record whether there is erythema, edema, ulceration, pigmentation, rough skin, thin skin, etc. at the medication site.

[0233] The test results are shown in Table 6:

[0234] Table 6 Skin irritation test results

[0235]

[0236]

[0237] As can be seen from the data in Table 6, the suspension gel provided by the present invention is mild and non-irritating.

[0238] The applicant declares that the present invention uses the above-mentioned embodiments to illustrate a suspension gel for treating inflammatory skin diseases. However, the present invention is not limited to the above-mentioned embodiments, and it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvements to the present invention, equivalent replacements of various raw materials in the product of the present invention, addition of auxiliary ingredients, and selection of specific methods, etc., are all within the scope of protection and disclosure of the present invention.

Claims

1. A suspension gel for treating inflammatory skin diseases, characterized in that: The suspension gel comprises an oil phase component, an aqueous phase component and a gel phase component, wherein the oil phase component comprises an active ingredient, an antioxidant, a low-polarity ester oil, a non-polar ester oil, an emulsifier and a polar solvent, the aqueous phase component comprises an emulsifier and water, and the gel phase component comprises a gelling agent, a pH regulator and water; Wherein, the active ingredient is maxacalcitol; The antioxidant in the oil phase component is a combination of butylated hydroxytoluene and dl-α-tocopherol or a combination of butylated hydroxyanisole and dl-α-tocopherol; The mass ratio of butylated hydroxytoluene to dl-α-tocopherol is (1-50):1; the mass ratio of butylated hydroxyanisole to dl-α-tocopherol is (1-50):1; The low-polarity ester oil in the oil phase component is a combination of medium-chain triglycerides and isopropyl myristate; The mass ratio of the medium chain triglyceride to isopropyl myristate is (2-4):1; The non-polar ester oil in the oil phase component is light liquid paraffin; The co-emulsifier in the oil phase component is a combination of Span 80 and polyoxyethylene-35 castor oil; The mass ratio of Span 80 to polyoxyethylene-35 castor oil is (0.5-1.5):1; The polar solvent in the oil phase component includes any one of ethanol, isopropanol, propylene glycol, butylene glycol, polyethylene glycol, glycerol, ethylene glycol, ethylene glycol monomethyl ether, ethylene glycol monobutyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monobutyl ether, diethylene glycol monomethyl ether or diethylene glycol monoethyl ether, or a combination of at least two thereof; The mass percentage of the polar solvent in the oil phase component is 1-15%; The emulsifier in the aqueous phase component is poloxamer 188; The water in the aqueous phase component is purified water and / or degassed water; The gelling agent in the gel phase component is Carbomer Tr-1; The pH regulator in the gel phase component is any one of triethanolamine, citric acid, and sodium hydroxide, or a combination of at least two thereof; The water in the gel phase component is purified water and / or degassed water; The suspension gel is prepared by the following method, which comprises the following steps: mixing maxacalcitol, low-polar ester oil, non-polar ester oil, polar solvent, antioxidant and co-emulsifier to obtain an oil phase component; The mixing temperature of the oil phase components is 25-35°C and the mixing time is 1.5-2.5 h; The method for preparing the aqueous phase component comprises the following steps: mixing an emulsifier and water to obtain an aqueous phase component; The mixing temperature of the aqueous phase components is 25-35°C and the mixing time is 0.1-1 h; The preparation method of the gel phase component comprises the following steps: dispersing the gelling agent into water, adding a pH adjusting agent and mixing after the gelling agent is completely swollen, thereby obtaining the gel phase component; The mixing temperature of the gel phase components is 25-35°C and the mixing time is 5-10 h; The oil phase component and the water phase component are mixed and emulsified, and then the gel phase component is added and mixed to obtain the suspension gel; The emulsification temperature is 15-40°C and the time is 0.5-5 h; The temperature for mixing the gel phase components is 25-35° C. and the time is 0.5-2 h.

2. The suspension gel according to claim 1, characterized in that The suspension gel is an O / W type gel, and the mass ratio of the oil phase component, the water phase component and the gel phase component is (50-70):(6-12):(20-40).

3. The suspension gel according to claim 1, characterized in that The mass ratio of the active ingredient to the antioxidant is (0.001-0.2):(0.005-0.5).

4. The suspension gel according to claim 1, characterized in that The mass ratio of the low-polar ester oil, the non-polar ester oil and the co-emulsifier is (10-80):(5-20):(0.5-5).

5. The suspension gel according to claim 1, characterized in that The mass ratio of the emulsifier to water in the aqueous phase component is (0.5-3): (5-10).

6. The suspension gel according to claim 1, characterized in that The mass ratio of the gelling agent, pH adjusting agent and water in the gel phase component is (0.04-0.75):(0.3-3):(15-40).

7. The suspension gel according to claim 1, characterized in that The pH value of the gel phase is 5.5-7.

0.

8. The suspension gel according to claim 1, characterized in that The average particle size of the suspension gel is 1-10 μm.

9. The suspension gel according to claim 1, characterized in that The suspension gel comprises the following components by weight percentage: Maxacalcitol 0.0001-0.01% Medium chain triglycerides 20-30% Isopropyl myristate 5-15% Light liquid paraffin 10-20% Polar solvent 5-15% Antioxidant 0.005-0.5% Span 80 0.5-2% Polyoxyethylene-35 castor oil 0.5-2% Poloxamer 188 0.5-3% Carbomer Tr-1 0.04-0.75% pH adjuster 0.3-3% Water 15-45%.

10. Use of the suspension gel according to any one of claims 1 to 9 in the preparation of a drug for treating inflammatory skin diseases.